Search results
People also ask
Should obstructive pulmonary disease be treated with triple therapy?
What is triple therapy for chronic obstructive lung disease?
What is triple inhaled therapy for chronic obstructive pulmonary disease (COPD)?
Does triple therapy improve lung health in patients with COPD?
Jul 5, 2021 · Based on current evidence, triple therapy should be considered in patients who have frequent or severe exacerbations, have received “open triple” combinations or LABA/ICS or LAMA/LABA or single bronchodilator treatment, or have a history of asthma or blood eosinophil counts ≥300 cells/μL.
- Beyond Dual Bronchodilation – Triple Therapy, When and Why
The evidence generated by pivotal RCTs supports the use of...
- Beyond Dual Bronchodilation – Triple Therapy, When and Why
Nov 6, 2018 · The Global Initiative for Obstructive Lung Disease (GOLD) management strategy recommend triple therapy with inhaled corticosteroids, LABA, and LAMA for GOLD group D patients who develop further exacerbations after receiving initial dual treatment of LABA and LAMA.3 4 Triple therapy using multiple inhalers has been shown to improve forced ...
- Yayuan Zheng, Jianhong Zhu, Yuyu Liu, Weiguang Lai, Chunyu Lin, Kaifen Qiu, Junyan Wu, Weimin Yao
- 2018
Jan 14, 2022 · The evidence generated by pivotal RCTs supports the use of triple therapy in patients who present for the first time and have severe airway obstruction, are symptomatic, have had frequent moderate or severe exacerbations in the previous year, and have peripheral eosinophilia.
- Time to First Exacerbation
- Lung Function
- Quality of Life
- Safety
In the TRINITY, TRILOGY and IMPACT studies the time to first moderate or severe exacerbation was significantly extended with triple therapy compared with LAMA/LABA, LABA/ICS and LAMA (Fig. 4). In the KRONOS study, the time to first moderate or severe exacerbation was extended with triple therapy; the improvement was significant with LAMA/LABA (haza...
In the three studies that assessed the single-inhaler triple therapy GLY/FOR/BDP (TRINITY, TRILOGY and TRIBUTE), triple therapy resulted in a significant change from baseline in pre-dose FEV1 compared with LAMA (61 mL; 95% CI: 37, 86; p < 0.0001 [52-week data]) , LABA/ICS (81 mL; 95% CI: 52, 109; p < 0.001 [26-week data], 63 mL; 95% CI: 32, 94; p <...
Across all the studies quality of life was assessed using the St. George’s Respiratory Questionnaire (SGRQ) . In the three studies that assessed the single-inhaler triple therapy GLY/FOR/BDP (TRINITY, TRILOGY and TRIBUTE), triple therapy resulted in greater improvement in SGRQ total score compared with TIO (at all timepoints except week 26 [weeks 4...
Across all the studies, SAEs were comparable between triple therapy and comparators. In the three studies that assessed the triple therapy GLY/FOR/BDP (TRINITY, TRILOGY and TRIBUTE), triple therapy was associated with a similar percentage of patients who experienced SAEs (13 –15% [17, 23]) compared with TIO (15%) , LABA/ICS (18%) and LAMA/LABA (17...
- Sue Langham, Jen Lewis, Nick Pooley, Nina Embleton, Julia Langham, MeiLan K. Han, James D. Chalmers
- 2019
Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2018; 19: 1279 – 1287.
- Lowie E.G.W. Vanfleteren, Anders Ullman, Anita Nordenson, Anders Andersson, Kristina Andelid, Leonar...
- 2019
Supplements. Cited by. PDF. Related. Does regular pharmacological treatment including inhaled corticosteroids (ICS) reduce mortality in patients with chronic obstructive pulmonary disease (COPD)?
Nov 9, 2017 · Triple therapy is recommended by the Global initiative for Chronic Obstructive Lung Disease (GOLD) for patients who experience recurrent exacerbations despite treatment with either a dual bronchodilator (preferred initial therapy) or LABA/ICS combination (alternative initial therapy).
